MYTHOS is an investigator-sponsored, randomized clinical trial designed to evaluate the effectiveness of RenalGuard Therapy® at reducing the incidence of Contrast-Induced Nephropathy (CIN). The study compares the rates of CIN in at-risk patient who receive induced diuresis with automated matched hydration therapy utilizing RenalGuard, compared to patients who receive standard overnight hydration. Final results were published in January 2012 in JACC – Cardiovascular Interventions.
Dr. Antonio Bartorelli and Dr. Giancarlo Marenzi, the principal investigators for the trial, reported on data from 170 patients with chronic kidney disease (CKD) who underwent elective or urgent percutaneous coronary interventions (PCI) in Italy. The results indicate that patients who were at higher risk for renal failure and who were treated with RenalGuard while undergoing imaging procedures developed CIN at a rate 74% lower than those who were treated with overnight hydration. The trial also found that patients treated with RenalGuard had significantly fewer in-hospital adverse events than those treated with overnight hydration.